Identification of interleukin-1 beta, but no other inflammatory proteins, as an early onset pre-eclampsia biomarker in first trimester serum by bead-based multiplexed immunoassays

Prenatal Diagnosis

Volumn 33, Issue 12, 2013, Pages 1183-1188

  Siljee, Jacqueline E ^a   Wortelboer, Esther J ^a,b   Koster, Maria P H ^a,b   Imholz, Sandra ^a   Rodenburg, Wendy ^a   Visser, Gerard H A ^b   de Vries, Annemieke ^a   Schielen, Peter C J I ^a   Pennings, Jeroen L A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA 2 MACROGLOBULIN; AMPHIREGULIN; BETACELLULIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EOTAXIN; EPIREGULIN; FETUIN A; FIBRINOGEN; GROWTH FACTOR; HAPTOGLOBIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTA PROTEIN 13; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROLACTIN; TENASCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOASSAY; MATERNAL SERUM; MULTIPLEXED IMMUNOASSAY; PREDICTION; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; VALIDATION PROCESS;

ADULT; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; FALSE POSITIVE REACTIONS; FEMALE; FIBRINOGEN; HUMANS; IMMUNOASSAY; INFLAMMATION; INTERLEUKIN-1BETA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES;

EID: 84889598191     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4219     Document Type: Article

References (40)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
2. Zwart JJ, Richters A, Ory F, et al. Eclampsia in the Netherlands. Obstet Gynecol 2008;112:820-7.
3. WHO. The World health report: 2005: make every mother and child count. Geneva: WHO Press, 2005.
4. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2008;2:249-59.
5. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797-803.
6. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.
7. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8.
8. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141-6.
9. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010; 221:363-78.
10. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11:309-16.
11. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4.
12. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5-15.
13. Visser N, van Rijn BB, Rijkers GT, et al. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv 2007;62:191-201.
14. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002;23:359-72.
15. Madazli R, Bulut B, Tuten A, et al. First-trimester maternal serum metastin, placental growth factor and chitotriosidase levels in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2012;164:146-9.
16. Kolla V, Jeno P, Moes S, et al. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol 2012; 2012: 305964.
17. Liu C, Zhang N, Yu H, et al. Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Placenta 2011; 32:168-74.
18. Rasanen J, Girsen A, Lu X, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res 2010; 9:4274-81.
19. Blankley RT, Gaskell SJ, Whetton AD, et al. A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. BJOG 2009; 116:1473-80.
20. Blumenstein M, McMaster MT, Black MA, et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009;9:2929-45.
21. Watanabe H, Hamada H, Yamada N, et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 2004;4:537-43.
22. Wortelboer EJ, Koster MP, Cuckle HS, et al. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG 2010;117:1384-9.
23. Cuckle HS, Wald N. Tests using single markers. In: Wald NJ, Leck I, editors. Antenatal and Neonatal Screening. 2nd ed. Oxford: Oxford University Press.2000;3-22.
24. Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 2011;66:225-39.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
26. Montagnana M, Lippi G, Albiero A, et al. Serum pro-inflammatory cytokines in physiological and pre-eclamptic pregnancies. Gynecol Endocrinol 2008; 24:113-6.
27. Kocyigit Y, Atamer Y, Atamer A, et al. Changes in serum levels of leptin, cytokines and lipoprotein in pre-eclamptic and normotensive pregnant women. Gynecol Endocrinol 2004; 19:267-73.
28. Kalinderis M, Papanikolaou A, Kalinderi K, et al. Elevated serum levels of interleukin-6, interleukin-1beta and human chorionic gonadotropin in pre-eclampsia. Am J Reprod Immunol 2011;66:468-75.
29. Casart YC, Tarrazzi K, Camejo MI. Serum levels of interleukin-6, interleukin-1beta and human chorionic gonadotropin in pre-eclamptic and normal pregnancy. Gynecol Endocrinol 2007;23:300-3.
30. Szarka A, Rigo J, Jr., Lazar L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59.
31. Alanbay I, Coksuer H, Ercan CM, et al. Chitotriosidase, interleukin-1 beta and tumor necrosis factor alpha levels in mild preeclampsia. Arch Gynecol Obstet 2012;285:1505-11.
32. Karehed K, Wikstrom AK, Olsson AK, et al. Fibrinogen and histidine-rich glycoprotein in early-onset preeclampsia. Acta Obstet Gynecol Scand 2010;89:131-9.
33. Schjetlein R, Haugen G, Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997;76:541-6.
34. Schjetlein R, Abdelnoor M, Haugen G, et al. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999;78:191-7.
35. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
36. Gordon YP, Grudzinskas JG, Jeffrey D, Chard T. Concentrations of pregnancy-specific beta 1-glycoprotein in maternal blood in normal pregnancy and in intrauterine growth retardation. Lancet 1977;1:331-3.
37. Pihl K, Larsen T, Laursen I, et al. First trimester maternal serum pregnancy-specific beta-1-glycoprotein (SP1) as a marker of adverse pregnancy outcome. Prenat Diagn 2009;29:1256-61.
38. Leong ASY, Cooper K, Leong FJWM. Manual of Diagnostic Antibodies for Immunohistology. 2 ed. London: Greenwich Medical Media.2003;51-2.
39. Akolekar R, Zaragoza E, Poon LC, et al. Maternal serum placental growth factor at 11+0 to 13+6weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-9.
40. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.